The Flowr Corporation (TSXV:FLWR) was featured in an article by The Growth Op regarding their strong management team and the company’s commitment to cultivating a high-quality, radiation-free cannabis products. According to the article, company co-founders Steve Klein and Tom Flow have contributed to the company’s success with their experience in the cannabis industry. Klein was a co-founder and managing member of Bengal Capital Trading LLC, which has a history of investing in technology and cannabis-related companies and Flow was a co-founder of one of Canada’s most profitable licensed producers, Medreleaf.

“This is our edge”, said Flowr CEO Vinay Tolia.“Tom, his team, and their expertise.”


Their expertise had led to Flowr’s partnership with Scotts’ Miracle-Gro (NYSE:SMG) subsidiary Hawthorne Gardening. As part of the agreement, Hawthorne funded the construction of a 50,000-square-foot R&D facility at the company’s Kelowna facility. The research conducted at the facility will predominately be centred around plant genetics and integrated growing systems, which will be applied to the company’s mission of providing the market with premium-quality, non-irradiated cannabis flower.

While the genetics of the plant are important Tolia was quick to point out that the care of the plant is as important, if not more so, than the genetics of the plant. The comapny holds itself to high standards of safety and cleanliness, which they’ve applied to their plants and hope that this commitment to creating a premium product translates to consumers.

“It’s not just about the genetics,” said Tolia. “It’s about the care. People like to say that genetics are the most important, but without proper care, [the genetics] won’t matter.”

To view the full article, click here.

Click here to connect with The Flowr Corporation (TSXV:FLWR) for an Investor Presentation.

Source: www.thegrowthop.com

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less